Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 994,959 | 1,000,899 | 285,908 | 652,664 | 2,346,081 |
| Depreciation Amortization | 5,023,214 | 3,680,554 | 2,443,959 | 1,251,957 | 4,916,560 |
| Accounts receivable | 104,218 | -399,792 | -504,259 | -659,723 | 555,940 |
| Accounts payable and accrued liabilities | -68,276 | 139,992 | -342,785 | -252,989 | -627,550 |
| Other Working Capital | -1,818,557 | -2,144,577 | -1,030,563 | -1,595,685 | -843,911 |
| Other Operating Activity | 707,215 | 699,666 | 1,157,745 | 1,278,296 | 883,835 |
| Operating Cash Flow | $4,942,773 | $2,976,741 | $2,010,005 | $674,520 | $7,230,955 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,151,017 | -831,504 | -520,722 | -335,406 | -1,033,743 |
| Net Acquisitions | 137,717 | 2,482 | 2,519 | 2,716 | 58,889 |
| Purchase Of Investment | -46,685 | -32,123 | -15,622 | -4,920 | -75,117 |
| Sale Of Investment | 55,345 | 7,405 | 4,354 | 3,964 | 164,680 |
| Purchase Sale Intangibles | -2,106,639 | -1,941,536 | -1,762,784 | -1,629,944 | -3,648,437 |
| Other Investing Activity | -2,196,008 | -1,882,430 | -1,727,581 | -1,612,023 | -3,607,263 |
| Investing Cash Flow | $-3,200,648 | $-2,736,170 | $-2,257,052 | $-1,945,669 | $-4,492,555 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 690,000 | 680,000 | 690,000 | 730,000 | 555,000 |
| Debt Repayment | -2,214,217 | -2,181,556 | -1,698,028 | -730,642 | -2,639,358 |
| Common Stock Repurchased | -16,049 | -15,817 | -16,049 | -16,980 | -199,275 |
| Dividend Paid | -1,981,597 | -1,890,822 | -964,696 | -954,446 | -2,067,678 |
| Other Financing Activity | 1,076,393 | 1,394,083 | 619,585 | 550,289 | -896,384 |
| Financing Cash Flow | $-2,445,470 | $-2,014,112 | $-1,369,188 | $-421,779 | $-5,247,695 |
| Exchange Rate Effect | 180,808 | 106,379 | 129,437 | 107,741 | 169,675 |
| Beginning Cash Position | 3,681,357 | 3,628,004 | 3,681,357 | 3,894,769 | 6,287,743 |
| End Cash Position | 3,158,820 | 1,960,841 | 2,194,552 | 2,309,574 | 3,948,122 |
| Net Cash Flow | $-522,537 | $-1,667,163 | $-1,486,805 | $-1,585,195 | $-2,339,621 |
| Free Cash Flow | |||||
| Operating Cash Flow | 4,942,773 | 2,976,741 | 2,010,005 | 674,520 | 7,230,955 |
| Capital Expenditure | -1,210,398 | -890,011 | -578,248 | -335,486 | -1,040,862 |
| Free Cash Flow | 3,732,375 | 2,086,730 | 1,431,757 | 339,034 | 6,190,093 |